How to Get AndroGel in Colorado

What Is AndroGel and Why Does It Require a Prescription?

AndroGel is a topical testosterone gel approved by the FDA for replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone, a condition called male hypogonadism. Because testosterone is classified as a Schedule III controlled substance under the Controlled Substances Act, every prescription requires documented clinical and biochemical evidence of deficiency.

The Endocrine Society's 2018 clinical practice guideline recommends TRT only for men with "unequivocally low serum testosterone levels" combined with consistent signs and symptoms. "Unequivocally low" means a morning total testosterone below 300 ng/dL confirmed on two separate draws. The guideline explicitly advises against prescribing testosterone to men who plan to conceive in the near term, given the drug's suppressive effect on spermatogenesis.

AbbVie's branded AndroGel comes in two concentrations: the original 1% formulation and the 1.62% formulation. The 1.62% gel demonstrated bioequivalent steady-state testosterone levels at a lower volume, which many patients find more convenient. Generic testosterone gel 1% is also widely available and considerably less expensive at Colorado pharmacies.

Colorado Telehealth Rules for Testosterone Prescribing

Colorado law permits full telehealth prescribing for Schedule III controlled substances. A provider licensed in Colorado can evaluate a patient by synchronous audio-video visit, order labs, and transmit an electronic prescription to any Colorado pharmacy. This is the fastest path for most patients.

The Colorado Medical Board requires that the provider-patient relationship be established before prescribing, but a telehealth encounter satisfies that requirement under the state's 2020 telehealth parity statute. There is no mandatory in-person visit for testosterone gel. Providers must still follow DEA rules for Schedule III e-prescribing, which means using a CEHRT-certified e-prescribing system with two-factor authentication.

Several national men's health platforms now serve Colorado. HealthRX, for example, pairs patients with licensed providers who can order labs from any Quest or Labcorp location in the state and send prescriptions to the patient's preferred pharmacy. Visits are typically completed within 48 hours. Rural Colorado patients in areas like the Western Slope or the San Luis Valley benefit most from telehealth, since endocrinology offices are concentrated along the Front Range.

Required Labs Before an AndroGel Prescription

No ethical provider will prescribe testosterone without laboratory confirmation. Two fasting, morning (before 10 a.m.) total testosterone levels below 300 ng/dL are the threshold most insurers and the Endocrine Society guideline recognize.

Beyond total testosterone, a complete pre-TRT workup typically includes:

• Free or bioavailable testosterone. Particularly useful when SHBG is elevated, as total testosterone alone can be misleading. The Endocrine Society notes that free testosterone "should be measured when total testosterone is near the lower limit" of the normal range.
• Complete blood count (CBC). Baseline hematocrit is essential because testosterone stimulates erythropoiesis. The TTrials consortium found that testosterone treatment increased hematocrit meaningfully in older men, requiring monitoring.
• PSA. The American Urological Association recommends PSA screening before initiating TRT in men over 40, with follow-up at 3 to 6 months after starting therapy.
• Lipid panel. Testosterone therapy can alter HDL cholesterol. The Testosterone Trials (TTrials) involving 790 men aged 65 and older showed modest reductions in HDL during 12 months of transdermal testosterone use.
• LH and FSH. Differentiates primary (testicular) from secondary (pituitary/hypothalamic) hypogonadism, which affects treatment decisions.

Colorado has more than 120 Quest Diagnostics and Labcorp patient service centers. Most telehealth platforms send a lab requisition electronically within hours of the initial consultation. Results typically return within 2 to 3 business days.

Who Can Prescribe AndroGel in Colorado?

Colorado grants prescriptive authority to several provider types. MDs and DOs have unrestricted prescribing privileges for Schedule III substances. Nurse practitioners hold full practice authority in Colorado under state statute 12-255-112, meaning they can prescribe testosterone independently without physician oversight after meeting postgraduate practice requirements. Physician assistants may prescribe under a collaborative agreement with a supervising physician.

For testosterone prescribing specifically, the Endocrine Society recommends that the prescribing clinician have training in recognizing the signs of hypogonadism and in monitoring for adverse effects such as polycythemia. Patients choosing a telehealth provider should confirm the clinician is licensed by the Colorado Department of Regulatory Agencies (DORA) and holds a valid DEA registration.

A board-certified endocrinologist or urologist may be appropriate for complex cases such as Klinefelter syndrome, pituitary tumors, or men with a history of prostate cancer. For straightforward age-related hypogonadism confirmed by labs, a primary care physician, NP, or PA with hormonal health experience is sufficient.

Insurance Coverage and Prior Authorization in Colorado

Commercial insurance in Colorado covers AndroGel and generic testosterone gel for diagnosed male hypogonadism, but nearly every plan requires prior authorization. PA requests typically demand documentation of two low morning testosterone levels, a list of symptoms (fatigue, low libido, depressed mood), and confirmation that the patient has no contraindications such as untreated polycythemia or breast cancer.

Colorado Medicaid does not cover AndroGel for standard male hypogonadism. Coverage is limited to a narrow type 2 diabetes indication. This leaves Medicaid-enrolled patients with several alternatives:

1. Generic testosterone gel 1%. Some Medicaid Managed Care Organizations in Colorado have placed generic testosterone gel on their formulary with step therapy. Ask your provider to submit a formulary exception request citing the Endocrine Society clinical practice guideline.
2. AbbVie's copay card. Commercially insured patients can reduce out-of-pocket costs for branded AndroGel to as little as $0 per month, though this does not apply to government insurance programs.
3. Compounded testosterone gel from a 503A pharmacy. This is often the most affordable route and is discussed below.

For patients with commercial insurance, the PA process usually takes 3 to 7 business days. Many telehealth platforms handle the PA submission on the patient's behalf. If denied, Colorado law requires insurers to provide an external review process consistent with ACA provisions.

503A Compounding Pharmacies in Colorado

Colorado licenses 503A compounding pharmacies under the State Board of Pharmacy. These pharmacies prepare testosterone gel from USP-grade testosterone powder in response to a patient-specific prescription. This is legal under section 503A of the Federal Food, Drug, and Cosmetic Act and does not require an FDA-approved NDA.

Compounded testosterone gel typically costs $30 to $80 per month without insurance, compared to $500 or more for branded AndroGel at a retail pharmacy. Compounded formulations can also be customized. Some patients receive testosterone combined with other agents or in concentrations not available commercially.

A 503A pharmacy in Colorado can dispense compounded testosterone gel in-state directly or by mail to a Colorado address. Interstate shipping of compounded controlled substances introduces additional DEA requirements, but for Colorado residents filling at a Colorado 503A pharmacy, the process is straightforward: the prescriber sends the prescription electronically, and the pharmacy ships within state board guidelines. Patients should verify that the pharmacy holds a current Colorado Board of Pharmacy license and follows USP 795 compounding standards.

How Long Until You Receive AndroGel in Colorado?

The timeline from initial consultation to first gel application typically spans 5 to 14 days. Here is the typical sequence:

Days 1 to 2: Schedule and complete a telehealth consultation. If the provider orders labs, go to a Quest or Labcorp location for a morning blood draw.

Days 3 to 5: Lab results return. If testosterone is confirmed below 300 ng/dL on two draws (or if a prior qualifying result exists), the provider writes the prescription.

Days 5 to 7: Prescription is sent to the pharmacy. For commercial pharmacy fills, branded AndroGel or generic gel is usually available within 24 to 48 hours. For 503A compounded gel, allow 3 to 5 business days for preparation and shipping.

Days 7 to 14: If prior authorization is required, add 3 to 7 business days. Telehealth platforms that handle PA in-house can often shorten this window.

Patients transferring an existing prescription from another state can sometimes skip the lab waiting period if the records include two qualifying testosterone levels drawn within the past 6 to 12 months. The receiving provider must still perform an independent clinical evaluation.

Monitoring and Follow-Up After Starting AndroGel

Starting testosterone gel is not a one-time event. Ongoing monitoring protects patients from the most common adverse effects and ensures the dose is delivering therapeutic levels. The Endocrine Society recommends checking testosterone levels 3 to 6 months after initiation and then annually.

The most clinically significant risk is polycythemia. In the Testosterone Trials, which enrolled 790 men over age 65 at 12 U.S. academic centers, testosterone treatment was associated with increased coronary artery plaque volume by CT angiography, highlighting the importance of cardiovascular risk assessment. A 2023 TRAVERSE trial (N=5,246) of transdermal testosterone in men with hypogonadism and cardiovascular risk factors found the incidence of major adverse cardiovascular events was noninferior to placebo, providing reassurance for appropriately selected patients.

Your monitoring schedule should include:

• Hematocrit at 3, 6, and 12 months, then annually. If hematocrit exceeds 54%, the Endocrine Society recommends dose reduction or temporary discontinuation.
• PSA at 3 to 6 months and 12 months. A PSA velocity exceeding 1.4 ng/mL/year warrants urologic evaluation.
• Testosterone trough level drawn 2 to 4 hours after gel application (for 1.62%) or before the next application (for 1% gel). Target is 400 to 700 ng/dL per the AUA/Endocrine Society recommendation.
• Bone mineral density at 1 to 2 years if hypogonadism was associated with osteoporosis. The TTrials bone sub-study demonstrated improvements in volumetric bone mineral density at the spine and hip after 12 months of testosterone gel use.

Colorado telehealth providers can order these follow-up labs electronically and review results via video visit. Patients living in rural areas do not need to drive to a specialist office for routine monitoring.

AndroGel Application and Transfer Precautions

Proper application technique matters. The FDA label for AndroGel warns about secondary exposure: testosterone gel can transfer from skin to another person through direct contact. This is a particular concern for female partners and children, where exposure can cause virilization symptoms.

Key application rules:

• Apply to clean, dry, intact skin on the shoulders, upper arms, or abdomen (depending on the formulation).
• Wash hands thoroughly with soap and water after application.
• Cover the application site with clothing once the gel is dry (usually within 5 to 10 minutes).
• If skin-to-skin contact with another person occurs at the application site, that person should wash the contacted area immediately.

The FDA's 2015 boxed warning on all testosterone products also notes the potential cardiovascular risks and restricts the approved indication to men with documented hypogonadism caused by specific medical conditions, not age-related decline alone. Colorado providers should document the underlying etiology in the patient's chart.